Patients with heart stents have similar increased risk of death from bleeding and heart attacks

April 8, 2015 by Scott Maier, University of California, San Francisco
Myocardial Infarction or Heart Attack. Credit: Blausen Medical Communications/Wikipedia/CC-A 3.0

In patients who received a stent to treat coronary artery blockage, those who experienced bleeding requiring hospitalization in the years after the procedure faced an increased risk of death that was similar to the risk faced by those who subsequently had heart attacks, according to a study of nearly 33,000 patients by UC San Francisco and Kaiser Permanente.

"Every year, 600,000 patients in the United States receive a and are given drugs that prevent the formation of clots within the stent. These drugs prevent heart attacks but increase the risk of ," said lead author Dhruv Kazi, MD, MSc, MS, an assistant professor of medicine at UCSF. "These bleeds are often written off as a side effect, but it turns out that they may be just as bad for patients as the heart attacks we're trying to avoid."

The study in the April 14 issue of the Journal of the American College of Cardiology is the first to show that the two risks are of comparable magnitude.

Kazi said that the results underline the importance of treating cardiac patients based on personalized risk factors, instead of using what he called a "one-size-fits-all" approach based on population statistics. This study points toward the possibility of using other information about patients that may help identify the antiplatelet drug that is most likely to be the most safe and effective for individual patients in the long run.

The study authors analyzed the records of 32,906 patients in the Kaiser Permanente Northern California health care system who received stents between 1996 and 2008 and were followed for four years. They found that both post-procedure and episodes of bleeding requiring hospitalization were associated with a greater relative risk of death (91 percent and 61 percent, respectively) over the same time span. The risks in the two groups were not different statistically, so the researchers could not say the risk for one was greater than the other.

Senior author Alan S. Go, MD, of the Kaiser Permanente Division of Research, noted that the study results "highlight the need for and value of high-quality outcomes research using data from patients treated in the real world to inform patients and doctors about the consequences of treatments."

Randomized trials, Go observed, "can tell us whether or not a drug, such as an antiplatelet medication, works. But patients enrolled in these trials are highly selected and may not really be like the we treat in the clinical practice and are usually followed for a short period of time."

In contrast, Go said, when rigorously evaluated, data collected in everyday clinical practice can yield valuable insights about long-term effectiveness and safety that complement what is learned from .

"We've known for some time that bleeds that occur during the stent procedure are bad for the patient, so we increasingly take steps to reduce those bleeds, such as giving drugs with lower bleeding risk and using the radial artery to perform the procedure instead of the femoral artery," Kazi said. "This is the first study to show that bleeds that occur in the months and years after discharge are also bad for the patient, emphasizing the need for long-term strategies that reduce a patient's risk of bleeding."

Explore further: Duration of antiplatelet therapy following PCI, risk of adverse events

Related Stories

Duration of antiplatelet therapy following PCI, risk of adverse events

March 17, 2015
An additional 18 months of dual antiplatelet therapy among patients who received a bare metal coronary stent did not result in significant differences in rates of stent thrombosis (formation of a blood clot), major adverse ...

Heart bypass surgery outperforms new generation stents

March 16, 2015
Despite the advent of a new generation of stents, patients with multiple narrowed arteries in the heart who received coronary artery bypass grafting fared better than those whose arteries were opened with balloon angioplasty ...

No mortality benefit of bypass surgery compared to latest generation of drug-coated stents

March 16, 2015
Newer drug-coated stents that keep arteries open have similar long-term rates of death compared with traditional bypass surgery for patients with more than one diseased coronary artery.

Complete angioplasty safe for certain heart attack survivors

March 17, 2015
Patients who experience the deadliest form of heart attack—ST segment elevation myocardial infarction (STEMI)—and suffer from substantial narrowing in multiple heart arteries may benefit from receiving angioplasty in ...

Anticoagulant linked with lower risk of death following heart attack compared to heparin

February 17, 2015
Patients who experienced a certain type of heart attack who received the anticoagulant fondaparinux had a lower risk of major bleeding events and death both in the hospital and after six months compared to patients who received ...

Extended post-stent treatment reduces risk of coronary thrombosis

November 17, 2014
Patients who took two anti-clotting medications beyond the standard 12 months after stent placement were significantly less likely to develop blood clots within their stents or to have a heart attack than those whose treatment ...

Recommended for you

New treatment significantly reduces cardiovascular events when combined with statins

November 12, 2018
Statins are the most commonly used treatment for cardiovascular disease. Despite reducing certain risk factors, if triglyceride levels remain high with use of statins, there is still a significant risk for heart attack, stroke ...

Kawasaki disease: One disease, multiple triggers

November 12, 2018
Researchers at University of California San Diego School of Medicine, Scripps Institution of Oceanography, and international collaborators have evidence that Kawasaki Disease (KD) does not have a single cause. By studying ...

Study: How vitamin D and fish oil affect risk of heart attack, stroke and cancer

November 12, 2018
For years, it's remained an open question: What effects do dietary supplements such as high doses of vitamin D or omega-3 fatty acids derived from fish oil have on the risk of diseases such as heart attack, stroke and cancer? ...

Diabetes drug might also ease heart failure risks

November 12, 2018
(HealthDay)—The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows.

Updated cholesterol guidelines offer more personalized risk assessment, additional treatment options

November 12, 2018
More personalized risk assessments and new cholesterol-lowering drug options for people at the highest risk for cardiovascular disease (CVD) are among the key recommendations in the 2018 cholesterol guidelines from the American ...

Heart meeting features fish oil, vitamin D, cholesterol news

November 11, 2018
Fish oil, vitamin D, novel drugs, new cholesterol guidelines: News from an American Heart Association conference over the weekend reveals a lot about what works and what does not for preventing heart attacks and other problems.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.